Mucosal melanoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Mucosal melanoma arises from melanocytes that reside in a range of internal epithelial tissues of ectodermal origin. The oral cavity, nose and paranasal sinuses, genital tract, and anorectal region are the commonest primary sites for mucosal melanoma.
Epidemiology-
Mucosal melanoma is a rare disease,
accounting for only 0.03% of new cancer diagnoses, According to Thelansis
disease modeling data, results of literature reviews, surveys, and registry
analyses, estimated 93,760 cases of melanoma were diagnosed in the United
States in 2020, ~1.6% of them are on the mucosal surfaces of the body.
The competitive
landscape of Mucosal melanoma includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Mucosal
melanoma across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Mucosal
melanoma Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 CM082 plus JS001 AnewPharma Phase 2
2 Nemvaleukin Alfa Subcutaneous Alkermes, Inc. Phase
2
3 Ipilimumab Bristol-Myers
Squibb Phase 2
4 Atezolizumab Hoffmann-La
Roche Phase 2
5 Imatinib Novartis Phase 2
6 APG-115+Pembrolizumab Ascentage
Pharma Group Inc. Phase 2
7 Pembrolizumab Emory
University Phase 1
8 Epacadostat Incyte
Corporation Phase 2
9 IMCgp100 Immunocore
Ltd Phase 2
10 ABI-007 Celgene Phase 2
Continue.
Comments
Post a Comment